Rituximab and Other New Anti-CD20 MAbs for Non-Hodgkin’s Lymphoma Treatment - European Medical Journal

Rituximab and Other New Anti-CD20 MAbs for Non-Hodgkin’s Lymphoma Treatment

Oncology
Download PDF
Authors:
*Letizia Polito, Massimo Bortolotti, Stefania Maiello, Maria Giulia Battelli, Andrea Bolognesi
Disclosure:

No potential conflict of interest.

Received:
01.04.14
Accepted:
18.06.14
Citation
EMJ Oncol. ;2[1]:63-69.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Abstract

Non-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of different haematological cancers with a wide range of aggressiveness. NHLs represent >80% of lymphomas and the majority of NHLs involve B cells. CD20 represents a good target for NHL immunotherapy because it is largely expressed on B cell NHL and not on B cell precursors and plasma cells. The anti-CD20 monoclonal antibody (mAb) rituximab (RTX) was the first antibody approved by the FDA for lymphoma therapy and has revolutionised B cell lymphoma treatment. Several clinical trials have demonstrated the high efficacy of RTX, resulting in a significant improvement in overall response rates and in NHL patient survival. However, RTX, both as a single agent and in combination with chemotherapy, induces several side-effects and resistance mechanisms. Remarkable efforts have been made to improve RTX efficacy, including conjugation to an active moiety (radionuclide, toxin, enzyme, or drug) and the development of new anti-CD20 mAbs. This review summarises the characteristics of RTX and other anti-CD20 mAbs for NHL treatment; the results of the main clinical trials are reported.

Please view the full content in the pdf above.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now